Eli Lilly

“Building a supercomputer on our, on-prem for us, really just to run proprietary drug discovery models. We think it's the biggest biologically focused supercomputer there is. And certainly the biggest pharma's done. Yes. With B 300 latest chipset.”

“We actually have a rule to like never decide in one meeting.”

“We'll spend almost 25% of sales this year. John Collison: I liked your way of putting us that you spend more on medical R&D than Germany does. Dave Ricks: Yes. Dave Ricks: Yeah. Dave Ricks: We're at the nation state level. It'll be, you know, fourteen billion …”

“Now, by happy accident, we are all now really pleased with, like, incretins, like our trisepetide to run them because they frequently demonstrate massive benefit. Uncardiovascular. And in some ways, it creates a barrier to entry for the next low-cost Chinese p…”

“And the current pricing isn't going to stay. Let's be honest. There'll be more competition. The government wants to lower our prices.”

“We have a medicine development that will Knock down your LDL, if it's safe enough, and then one undone, PCSK nine edit in your liver, and presumably that will last the rest of your life, and your LDLs will be between 20 and 40 forever.”

“It's conceivable that one could create like a licensing concept, stealing from the SAS model, where you say, we'll do the procedure for free. And as long as it's working for you will deposit X amount in our bank account, and you're getting the value, and we're…”

“Our actual net on insulin really hasn't changed. It's like 30 or 40 dollars, but the list price got up to two 75.”

“In the first year, no formularies covered this. So it was really only for that cash payer. No insurance company picked it up, even though it was dramatically cheaper. Now it's about half of the volume, but still half not because that model of this margin sprea…”

“There is no doubt in my mind. We are faster, more robust, probably cheaper than actually every biotech out there trying to do their own early phase clinical trials.”

“We built a monoclonal antibody biotech hub there. It's produced like a third of the medicines we've made since we started. Hugely successful. There's 400 employees.”

“We have a study reading out toward the end of this year in chronic knee pain. It's going to work.”

“So we're doing a study with our psoriasis drug, Taltz, and ZepBound. That will read out this fall. And I'm certain we'll show a boost in efficacy with the weight loss.”

“Actually, the number one prescribed form of these medications is Zep-bound self-buy. We sell more than that than our insured business, a new patient starts, and more than all of we go.”

“70% of our spend now is not on linear TV. So most of the advertising is more served up and in your search sequence, and increasingly we're interested in like, generative AI optimization.”

“And there's been studies on this of medical inventions that are not promoted... It's about a sixteen-year path to full adoption. With the medicine promoted, it's half that. We have an internal goal to half that again, to get to four years, to full whatever it …”

“Today we'll annualize, you know, in the billions of dollars. I think it's the largest Prescription platform online in terms of revenue. We run it on Stripe, I think, and going north from here.”

“40 year to date.”

“I think Terseptide's U.S. Patent is late thirties or foregrip on the oral beyond that.”

“Right now in the US, across all forms of GLP-ONE, on new patient capture, we're basically 70, 75% right now.”

“You know, there's no limit to human disease, and actually the longer we help people live, the more disease they'll be.”

“I have a belief that if you're not generating, to generate double digit growth in the sector, you need to invest at 20 to 25% of sales in R&D. That's sort of a good, a positive return R&D stack.”

“Like we talked about LP a earlier. That was the case there. We discarded the antibody. There is one that's been developed. And we went after the small molecule and the siRNA. They're both in phase three.”

“We've had a 150 years of that, and I'm the 11th CEO of the company. That's one less than Pope's in that period of time. So that's, it was a special honor, actually, and it's not a lifetime appointment. I can be fired any day, but the first four were family mem…”

“So we're growing R&D high teens, early low twenties. We're growing headcount in R&D single digits.”

“Well, I think that Mangiorno, probably by 2030, the pundits say, Probably will be over thirty billion dollars a year, well over thirty billion.”

“Lily, I think, the profile on a Lily molecule, molecule is far more beneficial than the Novo, but Novo's got a great product, too.”